Coagulase-negative staphylococci (CNS), which historically have been viewed as contaminants when recovered in culture media, are now recognized as opportunistic pathogens of increasing importance in hospital-acquired infections. They are frequently found colonizing prosthetic devices and intravenous lines. CNS are capable of producing a variety of infections including deep-seated infections such as endocarditis and meningitis. Staphylococcus epidermidis is the most commonly isolated CNS and it appears to be the most resistant to antibiotics, making antimicrobial therapy challenging. Treatment of the infection will very often require removal of a prosthetic device, if present. An adequate infection control program is imperative in prophylaxis against this infection.
Get full access to this article
View all access options for this article.
References
1.
DavenportDSMassanariRMPfallerMABaleMJStreedSAHierholzerWJ. Usefulness of a test for slime production as a marker for clinically significant infections with coagulase-negative staphylococci. J Infect Dis1986; 153: 332–9.
2.
BrumfittWHamilton-MillerJMT. Coagulase-negative staphylococci. Int J Dermatol1983; 22: 232–4.
3.
GemmellCG. Coagulase-negative staphylococci. J Med Microbiol1986; 22: 285–95.
4.
PascualAFleerAWesterdaalNACVerhoefJ. Modulation of adherence of coagulase-negative staphylococci to Teflon catheters in vitro. Eur J Clin Microbiol1986; 5: 518–22.
5.
LeightonPMLittleJA. Identification of coagulase-negative staphylococci isolated from urinary tract infections. Am J Clin Pathol1986; 85: 92–5.
6.
DaviesAJStoneJW. Current problems of chemotherapy of infections with coagulase-negative staphylococci. Eur J Clin Microbiol1986; 5: 277–81.
ArcherGL. Staphylococcus epidermidis and other coagulase-negative staphylococci. In: MandellGLDouglasRGBennettJE, eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1990: 1511–8.
9.
WestTEWalsheJJKrolCPAmsterdamD. Staphylococcal peritonitis in patients on continuous peritoneal dialysis. J Clin Microbiol1986; 23: 809–12.
10.
RubinMHathornJWMarshallDGressJSteinbergSMPizzoPA. Gram-positive infections and the uses of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med1988; 108: 30–5.
11.
HerwaldtLMoriM. Coagulase-negative staphylococcal bacteremia: true positive infection rate (abstract 1265). Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989: 316.
12.
SidebottomDGFreemanJPlattREpsteinMFGoldmannDA. Fifteen year experience with bloodstream isolates of coagulase-negative staphylococci in neonatal intensive care. J Clin Microbiol1989; 26: 713–8.
TomaszADrugeonHBDelencastreHMJabesDMcDougallLBilleJ. New mechanism for methicillin resistance in Staphylococcus aureus: Clinical isolates that lack the PBP 2a gene and contain normal penicillin-binding proteins with modified penicillin-binding capacity. Antimicrob Agents Chemother1989; 33: 1869–74.
19.
TollefsonDFBandykDFKaebnickHWSeabrookGRTowneJB. Surface biofilm disruption—enhanced recovery of microorganisms from vascular prostheses. Arch Surg1987; 122: 38–43.
20.
FarberBFKaplanMHGlogstonAG. Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics. J Infect Dis1990; 161: 37–40.
FransonTRShethNKMenonLSohnlePG. Persistent in-vitro survival of coagulase-negative staphylococci adherent to intravascular catheters in the absence of conventional nutrients. J Clin Microbiol1986; 24: 559–61.
23.
BeamanMSolaroLAduDMichaelJ. Peritonitis caused by slime producing coagulase negative staphylococci in continuous ambulatory peritoneal dialysis (letter). Lancet1987; 1: 42.
24.
KristinssonKGSpencerRCBrownCB. Clinical importance of production of slime by coagulase-negative staphylococci in chronic ambulatory peritoneal dialysis (letter). J Clin Pathol1986; 39: 117–8.
25.
GrayECPetersGVerstegenMRegelmannWE. Effect of extracellular slime substance from Staphylococcus epidermidis on the human cellular immune response (letter). Lancet1984; 1: 365–7.
26.
KristinssonKGSpencerRC. Slime production as a marker for clinically significant infections with coagulase-negative staphylococci (letter). J Infect Dis1986; 154: 728–9.
27.
SchmittDDBandykDFPequettAJMalangoniMATowneJB. Mucin production by Staphylococcus epidermidis. Arch Surg1986; 121: 89–95.
28.
BykowskaKLudwickaAWegrzynowiczZLopaciukSKopecM. Anticoagulant properties of extracellular slime substance produced by Staphylococcus epidermidis. Thromb Haemost1985; 54: 853–6.
29.
BourgaultAMGauvreauL. Antimicrobial susceptibilities of coagulase-negative staphylococci isolated from urinary infections. Antimicrob Agents Chemother1983; 23: 793–5.
30.
FassRJHelselVLBarnishanJAyersLW. In vitro susceptibilities of four species of coagulase-negative staphylococci. Antimicrob Agents Chemother1986; 30: 545–52.
31.
RolstonKVIThirolfPHoDSBodeyGP. Species dependent variability in the susceptibility of coagulase-negative staphylococci to various antimicrobial agents. J Antimicrob Chemother1985; 16: 659–62.
32.
TuazonCUMillerH. Clinical and microbiologic aspects of serious infections caused by Staphylococcus epidermidis. Scand J Infect Dis1983; 15: 347–60.
33.
NeuHCChinNXLabthavikulP. Antibacterial activity of coumermycin alone and in combination with other antibiotics. Antimicrob Agents Chemother1984; 25: 687–9.
34.
KlineMWMasonEOKaplanSLLamberthLBJohnsonGS. Comparative in-vivo activity of LY 146032 and eight other antibiotics against gram-positive bacteria isolated from children. J Antimicrob Chemother1987; 20: 203–7.
35.
Del BeneVEJohnJFTwittyJALewisJW. Antistaphylococcal activity of teicoplanin, vancomycin, and other antimicrobial agents: The significance of methicillin resistance. J Infect Dis1986; 154: 349–52.
36.
DaviesAJClewettJJonesAMarshallR. Sensitivity patterns of coagulase negative staphylococci from neonates. J Antimicrob Chemother1986; 17: 155–60.
37.
WatanakunakornC. In-vitro activity of teicoplanin alone and in combination with rifampicin, gentamicin or tobramycin against coagulase-negative staphylococci. J Antimicrob Chemother1987; 19: 439–43.
38.
FassRJHelselVL. In-vitro activity of LY 146032 against staphylococci, streptococci and enterococci. Antimicrob Agents Chemother1986; 30: 781–4.
39.
EliopoulosGMGardellaAMoelleringRC. In-vitro activity of ciprofloxacin, a new carboxyquinolone antimicrobial agent. Antimicrob Agents Chemother1984; 25: 331–5.
40.
WolfsonJSHooperDC. The fluoroquinolones: Structure, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother1985; 28: 581–6.
41.
HartCAHowSJHobsonD. Activity of ciprofloxacin against genital tract pathogens. Br J Vener Dis1984; 60: 316–8.
KesadoTHashizumeTAshahiY. Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics. Antimicrob Agents Chemother1980; 17: 912–7.
44.
KahanFMKroppHSundelofJGBirnbaumJ. Thienamycin: Development of imipenam-cilastatin. J Antimicrob Chemother1983; 12 (suppl D):1–35.
45.
KroppHGerckensLSundelofJGKahanFM. Antimicrobial activity of imipenem: The first thienamycin antibiotic. Rev Infect Dis1985; 7 (suppl 3):S389–S410.
PohlodDJSaravolatzLDSomervilleMM. In-vitro susceptability of gram positive cocci to LY 146032, teicoplanin, sodium fusidate, vancomycin and rifampicin. J Antimicrob Chemother1987; 20: 197–202.
48.
ThomasMGLandSD. In-vitro activity of coumermycin against methicillin resistant staphylococci: A comparison with six other agents. J Antimicrob Chemother1986; 18: 171–5.
49.
RolstonKVAlvaresMEHoyJFAldermanHCHoDSBodeyGP. In-vitro activity of SCH 34343, a new penem, and other antimicrobial agents against clinical isolates from cancer patients. Chemotherapy1986; 32: 506–14.
50.
ProctorRAWickPHamillRJIn-vitro studies of antibiotic combinations for multiply resistant coagulase negative staphylococci. J Antimicrob Chemother1987; 20: 223–31.
51.
KentAFSpellerDCE. Sensitivity of urinary staphylococci to ciprofloxacin and acrosoxacin. Eur J Clin Microbiol1986; 4: 139–40.
52.
KuninCMSteeleC. Culture of the surface of urinary catheters to sample urethral flora and study the effect of antimicrobial therapy. J Clin Microbiol1985; 21: 902–8.
53.
ArditiMYogevR. In vitro interaction between rifampin and clindamycin against pathogenic coagulase-negative staphylococci. Antimicrob Agents Chemother1989; 33: 245–7.
54.
WilliamsFTBoeremaJBSummerenTR. The in-vitro comparative activity of quinolones against bacteria from urinary tract infections in general practice. J Antimicrob Chemother1986; 17: 69–73.
55.
SchwalbeRSStapletonJTGilliganPH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med1987; 316: 927–31.
56.
NeihartREFriedJSHodgesGR. Coagulase negative staphylococci. South Med J1988; 81: 491–500.
57.
FrongilloRFDonatiLFedericoGClinical comparative study on the activity of cefamandole in the treatment of serious staphylococcal infections caused by methicillin-susceptible and methicillin-resistant strains. Antimicrob Agents Chemother1986; 29: 789–96.
HackbarthCJChambersHF. Methicillin-resistant staphylococci: Detection methods and treatment of infections. Antimicrob Agents Chemother1989; 33: 995–9.
60.
SiebertWTMorelandNWilliamsTW. Synergy of vancomycin plus cefazolin or cephalothin against methicillin-resistant Staphylococcus epidermidis. J Infect Dis1979; 139: 452–7.
61.
SchwalbeRSRitzWJVermaPRBarrancoEAGilliganPH. Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus. J Infect Dis1990; 161: 45–51.
62.
SchwalbeRSStapletonJTGilliganPH. Vancomycin-resistant Staphylococcus (letter). N Engl J Med1987; 317: 767–8.
63.
FransonTRKammerRBCooperGLPrestonDABrowneRA. Vancomycin-resistant staphylococcus (letter). N Engl J Med1987; 317: 766–7.
64.
EisenbergES. Vancomycin-resistant staphylococcus (letter). N Engl J Med1987; 317: 766.
VendittiMSantiniCSerraPMicozziAGentileGMartinoP. Comparative in-vitro activities of new fluorinated quinolones and other antibiotics against coagulase-negative Staphylococcus blood isolated from neutropenic patients and relationship between susceptibility and slime production. Antimicrob Agents Chemother1989; 33: 209–11.
68.
SegretiJGvazdinskasLCTrenholmeGM. In vitro activity of minocycline and rifampin against staphylococci. Diagn Microbiol Infect Dis1989; 12: 253–5.
69.
FarberBFYeeYCKarchmerAW. Interaction between rifampin and fusidic acid against methicillin-resistant coagulase-positive and -negative staphylococci. Antimicrob Agents Chemother1986; 30: 174–5.
70.
ShalitIBergerSAGoreaAFrimermanH. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob Agents Chemother1989; 33: 593–4.
71.
KarchmerAW. Staphylococcal endocarditis: Laboratory and clinical basis for antibiotic therapy. Am J Med1985; 78 (suppl 6B):116–27.
72.
KarchmerAWArcherGLDismukesWE. Staphylococcus epidermidis causing prosthetic valve endocarditis: Microbiologic and clinical observations as guides to therapy. Ann Intern Med1983; 98: 447–55.
73.
HealyDPPolkREGarsonMLRockDTComstockTJ. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother1987; 31: 393–7.
74.
SwayneRRamplingANewsomSWB. Intraventricular vancomycin for treatment of shunt-associated ventriculitis. J Antimicrob Chemother1987; 19: 249–53.
75.
GruerLDBartlettRAyliffeGA. Species identification antibiotic sensitivity of coagulase negative staphylococci from CAPD peritonitis. J Antimicrob Chemother1984; 13: 577–84.
76.
PancorboSComtyC. Peritoneal transport of vancomycin in 4 patients undergoing continuous ambulatory peritoneal dialysis. Nephron1982; 31: 37–9.
77.
MatzkeGRZhanelGGGuayDRP. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet1986; 11: 257–82.
78.
MorseGDFarolinoDFApicellaMAWalsheJJ. Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother1987; 31: 173–7.
79.
MillerSJ. Catheter-related sepsis during parenteral nutrition. Hosp Pharm1988; 23: 991–6.
80.
Infection control. In: Accreditation manual for hospitals. Chicago: Joint Commission on Accreditation of Healthcare Organizations, 1989: 67–79.
81.
BozzettiFTernoGBonfantiG. Prevention and treatment of central venous catheter sepsis by exchange via a guidewire. Ann Surg1983; 198: 48–52.
82.
LevinAMasonAJJindalKKGoldsteinMBFongIW. The value of topical povidone-iodine ointment in the prevention of hemodialysis related sepsis (abstract 1078). Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989: 284.
83.
MakiDGBandJD. A comparative study of polyantibiotic and iodophor ointments in prevention of vascular catheter-related infection. Am J Med1981; 70: 739–44.
84.
FlowersRHSchwenzerKJKopelRFEfficacy of an attachable subcutaneous cuff for the prevention of intravascular catheter-related infection. A randomized, controlled trial. JAMA1989; 261: 878–83.
85.
MakiDGCobbLGarmanKShapiroJMRingerMHelgersonRB. An attachable silver impregnated cuff for prevention of infection with central venous catheters: A prospective randomized multicenter trial. Am J Med1988; 85: 307–14.
